Patient access and maintain six protected classes for depressions and schizophrenia under Medicare Part D; Inflation Reduction Act of 2022 implementation, Part D redesign phase-in for small companies;
Source-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 18, 2025
- Income
- Not reported
- Expenses
- $1,420,000.00
- Registrant
- ALKERMES, INC.
- Client
- ALKERMES, INC.
- Filing UUID
- 9907f4ca-5c2d-4ccf-9b80-7fe4f1c48bfd
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Policies impacting pharmaceutical development, reimbursement, and patient access and cost; Awareness of need for transparency and patient access within the 340B program; Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2026; PDUFA implementation and efficiency improvements at the FDA; H.R.1414 - Camerons Law; H.R.946 - ORPHAN Cures Act;
Literal federal measure citations: H.R. 2163, S. 464, H.R.1414, H.R.946
Expand funding and flexibility to address all substance use disorders;
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.